Due to its short half-life, its solution must be prepared frequently and administered as a continuous intravenous infusion” Kopeć et al (2018).
Epoprostenol sodium is recommended for the treatment of high-risk patients with pulmonary arterial hypertension. The use of high doses of this drug has been associated with long-term survival. Due to its short half-life, its solution must be prepared frequently and administered as a continuous intravenous infusion. According to the prescribing information, a solution of a new thermostable form of epoprostenol (Veletri; Actelion Pharmaceuticals, Allschwil, Switzerland) can be administered at room temperature for 48 hours, provided the concentration is >15,000 ng/ml.
Kopeć, G., Waligóra, M., Stępniewski, J. and Podolec, P. (2018) Indwelling central venous catheter occlusion during chronic epoprostenol infusion. The Journal of Heart and Lung Transplantation. March 30th. .